CM Life Sciences III (CMLT) executive Nallicheri received 9,530,394 shares

Insider transactions reported

Melanie Nallicheri (executive at CM Life Sciences III Inc., CMLT) reported that they received 9,530,394 shares on Dec 17, 2021. After these transactions the filing shows 5,679,247 shares held directly and 3,851,147 shares held indirectly (By MIN 2020 LLC).

Reporting person

Nallicheri Melanie

Options and other derivatives

Holdings before and after

• Common Stock: 0 to 5,679,247 direct
• Common Stock: 0 to 3,851,147 indirect, By MIN 2020 LLC
• Stock Option (Right to Buy): 0 to 1,253,999 direct
• Earn-out Shares: 0 to 1,035,655 direct
• Earn-out Shares: 0 to 527,558 indirect, By MIN 2020 LLC

Footnotes from the filing

1. 1. On December 17, 2021, upon consummation of the transactions (the Closing of the Business Combination ) contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the Merger Agreement ) by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., Legacy EQRx ), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock.
2. 2. Shares held by MIN 2020 LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any.
3. 3. These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the 2019 Plan ) and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock. One-fourth of the shares underlying this option vest and become exercisable on January 20, 2022 (the one-year anniversary of the grant date), with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each vesting date.
4. 4. These options were issued under the 2019 Plan and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock. The shares underlying this option vest and become exercisable in 48 equal monthly installments commencing September 1, 2021, subject to the Reporting Person's continuous service as of each vesting date.
5. 5. Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 1,563,213 shares of the Issuer's Common Stock (the Earn-out Shares ), (i) 1,094,250 of which will be released from escrow if the value weighted average price ( VWAP ) for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 468,963 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ